natgillin/translations-raw huggingface dataset:
• Are you taking any medicines containing: o azathioprine or other immunosuppressive agents (which are sometimes given to patients after a transplant operation), o cholestyramine (used to treat patients with high blood cholesterol), o rifampicin (antibiotic), o antacids or proton pump inhibitors (used for acid problem in your stomach such as indigestion), o phosphate binders (used in patients with chronic kidney failure to reduce the absorption of phosphate), o antibiotics (used to treat bacterial infections), o isavuconazole (used to treat fungal infections), o telmisartan (used to treat high blood pressure) o or any other medicines (including those you can buy without a prescription) that your doctor does not know about? 
• Ali morda jemljete zdravila, ki vsebujejo: o azatioprin ali druga imunosupresivna zdravila (bolniki jih včasih prejmejo po presaditveni operaciji), o holestiramin (uporabljajo ga za zdravljenje bolnikov z visokim holesterolom), rifampicin (antibiotik), o antacide ali zaviralce protonske črpalke (uporabljajo se pri težavah s kislino v želodcu, kot je dispepsija),
In patients with renal impairment in whom mycophenolate mofetil and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered the dose recommendations for ganciclovir should be observed and patients monitored carefully. 
Bolnike z ledvično okvaro, ki sočasno dobivajo zdravilo mofetilmikofenolat in ganciklovir oziroma njegova predzdravila, npr. valganciklovir, je treba skrbno nadzorovati in proučiti odmerjanje ganciklovirja.
No substantial alteration of MPA pharmacokinetics is anticipated and Myfenax dose adjustment is not required. 
Znatnih sprememb v farmakokinetiki mikofenolne kisline ni pričakovati, zato prilagajanje odmerkov zdravila Myfenax ni potrebno.
Changes to Myfenax therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8). 
Pri bolnikih s presadki se zaradi zmanjšanja tveganja za zavrnitev presadka spremembe v zdravljenju z zdravilom Myfenax lahko uvaja le pod ustreznim nadzorom (glejte poglavje 4.8).
Transparent PVC/PVdC - aluminium blisters in pack sizes of 100 or 300 or 100 x 1 capsules per carton. 
Prozorni PVC/PVdC - aluminijasti pretisni omoti v pakiranjih po 100 ali 300 ali 100 x 1 kapsula v škatli.
Myfenax film-coated tablets should be handled with care. 
Zdravilo Myfenax tablete je treba uporabljati previdno.
This means taking 3°tablets in the morning then 3°tablets in the evening. 
3 tablete vzemite zjutraj, 3 pa zvečer.
When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. 
Pri primerjavi deležev zavrnitve presadka ali deležev izgube presadka med bolniki, ki so jemali zdravilo Myfenax in zaviralce protonske črpalke ter bolniki, ki so jemali zdravilo Myfenax in niso jemali zaviralcev protonske črpalke, niso opazili značilnih razlik.
Isavuconazole An increase of MPA AUC0-∞ by 35% was observed with concomitant administration of isavuconazole. 
Pri sočasni uporabi izavukonazola so opazili povečanje AUC0-∞ mikofenolne kisline za 35 %.
Paediatric population aged 2 to 18 years The recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily). 
Priporočeni odmerek mofetilmikofenolata je 600 mg/m2, vzetih peroralno dvakrat na dan (do največ 2 g na dan).
Agitation, confusional state, depression, anxiety, thinking abnormal, insomnia 
Psihiatrične motnje zelo pogosti pogosti agitacija, stanje zmedenosti, depresija, anksioznost, nenormalno mišljenje, nespečnost
In patients with delayed renal graft function post-transplant, mean MPA AUC (0-12°h) was comparable to that seen in post-transplant patients without delayed graft function. 
Pri bolnikih z zapoznelim delovanjem ledvičnega presadka je bila srednja AUC (0 - 12 ur) mikofenolne kisline primerljiva s tisto pri bolnikih brez zapoznelega delovanja ledvičnega presadka.
Mean plasma MPAG AUC (0-12°h) was 2-3-fold higher than in post-transplant patients without delayed graft function. 
Srednja AUC (0 - 12 ur) mikofenolglukuronida pa je bila 2- do 3-krat večja kot pri bolnikih brez zapoznelega delovanja ledvičnega presadka.
Therapeutic drug monitoring of MPA may be appropriate when switching combination therapy (e.g. from ciclosporin to tacrolimus or vice versa) or to ensure adequate immunosuppression in patients with high immunological risk (e.g. risk of rejection, treatment with antibiotics). 
Pri zamenjavi kombiniranega zdravljenja (npr. z zdravljenja s ciklosporinom na zdravljenje s takrolimusom ali obratno) ali za zagotovitev ustrezne imunosupresije pri bolnikih z visokim imunološkim tveganjem (npr. tveganjem zavrnitve, zdravljenjem z antibiotiki) je primerno spremljanje terapevtskih koncentracij mikofenolne kisline.
Myfenax treatment should not be initiated in women of child bearing potential without providing a pregnancy test result to rule out unintended use in pregnancy (see section 4.6). 
Zdravljenja z zdravilom Myfenax ne smemo uvesti pri bolnicah v rodni dobi, ki ne zagotovijo izvida testa nosečnosti, da izključimo nenamerno uporabo zdravila med nosečnostjo (glejte poglavje 4.6).
Body: caramel opaque, printed ‘250' axially in black ink. 
Telo: karamelne barve s črnim napisom “250”v smeri osi kapsule.
values similar to those seen in adult renal transplant patients receiving mycophenolate mofetil at a dose of 1°g BID in the early and late post-transplant period. 
2 do 18 let), ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan. Ti odmerki so dali podobne vrednosti AUC mikofenolne kisline kot pri odraslih bolnikih z ledvičnim presadkom, ki so prejemali mofetilmikofenolat v odmerku 1 g dvakrat na dan v začetnem in poznejšem obdobju po presaditvi.
Multidrug resistance protein 1 (MDR1) is also able to transport MPA, but its contribution seems to be confined to the absorption process. 
Protein za multiplo odpornost na zdravila 1 (MDR1 - Multidrug resistance protein 1) je prav tako lahko prenašalec mikofenolne kisline,
Therefore Myfenax is contraindicated in pregnancy unless there are no suitable alternative treatments to prevent transplant rejection. 
Zato je zdravilo Myfenax med nosečnostjo kontraindicirano, razen če za preprečitev zavrnitve presadka ni na voljo primernih alternativnih zdravljenj.
Paediatric population < 2 years 
Pediatrični bolniki, mlajši od 2 let
It is recommended that mycophenolate mofetil should not be administered concomitantly with azathioprine because such concomitant administration has not been studied. 
Ne priporočamo sočasnega dajanja zdravila Myfenax in azatioprina, ker kombiniranega jemanja teh zdravil niso proučevali.
Patients with a body surface area greater than 1.5 m2 may be prescribed Myfenax capsules at a dose of 1 g twice daily (2 g daily dose). 
Bolnikom s telesno površino med 1,25 in 1,5 m2 predpišemo kapsule zdravila Myfenax v odmerku 750 mg dvakrat na dan (dnevni odmerek 1,5 g).
Following single dose administration of 1.5°g of mycophenolate mofetil to normal healthy subjects pre-treated with 4°g three times a day (TID) of cholestyramine for 4°days, there was a 40% reduction in the AUC of MPA (see section 4.4 and section 5.2). 
Če dajemo holestiramin 4 dni v odmerku 4 g trikrat na dan, ta zmanjša AUC mikofenolne kisline po enkratnem peroralnem vnosu 1,5 g mofetilmikofenolata za približno 40 % (glejte poglavje 4.4 in poglavje 5.2).
A reduction in the AUC of MPA of approximately 40% is associated with the co-administration of cholestyramine (4°g TID), indicating that there is a significant amount of enterohepatic recirculation. 
Holestiramin v odmerku 4 g 3-krat na dan zmanjša AUC mikofenolne kisline za približno 40 %, kar potrjuje veliko stopnjo ponovnega enterohepatičnega obtoka.
Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when mycophenolate mofetil was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection). 
Pri sočasnem dajanju mofetilmikofenolata in sevelamerja so opazili zmanjšanje Cmax mikofenolne kisline za 30 % in AUC0-12h mikofenolne kisline za 25 %, kliničnih posledic (zavrnitve presadka) pa ni bilo.
Myfenax is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection. 
Zdravilo Myfenax je med nosečnostjo kontraindicirano, razen če za preprečitev zavrnitve presadka ni na voljo primernega alternativnega zdravljenja.
• low/high blood pressure, widening of blood vessels 
• hitrejše bitje srca • nizek/visok krvni tlak, razširitev krvnih žil.
Microcrystalline cellulose Povidone K-30 
Jedro tablete mikrokristalna celuloza povidon K-30 magnezijev stearat premrežen natrijev karmelozat
• growth of the skin, rash, acne, hair loss 
• rast kože, izpuščaj, akne, izpadanje las
Elderly patients receiving Myfenax as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals. 
Pri starejših bolnikih, ki prejemajo zdravilo Myfenax kot del kombinacije imunosupresivnega režima, je v primerjavi z mlajšimi tveganje za pojav določenih okužb (vključno s citomegalovirusno tkivno invazivno boleznijo), krvavitev v prebavilih in pljučnega edema lahko večje.
Mycophenolate mofetil has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation. 
Pri bolnikih, ki so prejemali mofetilmikofenolat, so opazili povišano incidenco neželenih učinkov v prebavilih, vključno z redkimi primeri razjed v prebavnem traktu, krvavitvami in perforacijami črevesa.
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Myfenax. 
Pri bolnikih, zdravljenih z imunosupresivi, vključno z zdravilom Myfenax, so poročali o primerih nefropatije, povezane z virusom BK, kot tudi progresivne multifokalne levkoencefalopatije (PML), povezane z virusom JC.
Intravenous mycophenolate mofetil should be administered for the first 4°days following hepatic transplant, with oral Myfenax initiated as soon after this as it can be tolerated. 
Prve 4 dni po presaditvi jeter je treba dajati mofetilmikofenolat intravensko, takoj ko je bolnik sposoben požirati, pa nadaljujemo s peroralno obliko zdravila Myfenax.
• vomiting, stomach pain, diarrhoea, feeling sick 
• bruhanje, bolečine v trebuhu, driska in siljenje na bruhanje
• if you are planning to become pregnant, or if you get pregnant while taking Myfenax. 
- če nameravate zanositi ali zanosite med jemanjem zdravila Myfenax.
In contrast, if concomitant ciclosporin treatment is stopped, an increase in MPA AUC of around 30% should be expected. 
Mofetilmikofenolat ne vpliva na farmakokinetiko ciklosporina A. Če pa sočasno zdravljenje s ciklosporinom prekinemo, lahko pričakujemo povečanje AUC mikofenolne kisline za približno 30 %.
Do not take Myfenax if you are breast-feeding. 
Ne jemljite zdravila Myfenax, če dojite.
Capsule content Pregelatinised starch (maize) Povidone K-30 
Kapsula vsebuje: predgeliran koruzni škrob povidon K-30 premrežen natrijev karmelozat magnezijev stearat
This means taking 6°capsules in the morning then 6°capsules in the evening. 
6 kapsul vzemite zjutraj, 6 pa zvečer.
Acidosis, hyperkalaemia, hypokalaemia, hyperglycaemia, hypomagnesaemia, hypocalcaemia, hypercholesterolaemia, hyperlipidaemia, hypophosphataemia, hyperuricaemia, gout, anorexia Psychiatric disorders Very commonCommon 
Presnovne in prehranske motnje zelo pogosti pogosti acidoza, hiperkaliemija, hipokaliemija, hiperglikemija, hipomagnezemija, hipokalciemija, hiperholesterolemija, hiperlipidemija, hipofosfatemija, hiperurikemija, protin, anoreksija
Therefore women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting Myfenax therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. 
Zato morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Myfenax uporabljati vsaj eno zanesljivo obliko kontracepcije, razen če niso izbrale metode vzdržnosti (glejte poglavje 4.3).
Titanium dioxide (E171) 
titanov dioksid (E171) želatina
• alterations of the inner wall of the small intestine (intestinal villous atrophy) 
• spremembe notranje stene tankega črevesa (atrofije v črevesni votlini)
Myfenax 500 mg film-coated tablets 
Myfenax 500 mg filmsko obložene tablete
• constipation, indigestion, wind (flatulence), belching 
• zaprtje, prebavne motnje, vetrovi (napenjanje), spahovanje
Patients will be informed that they should not stop taking mycophenolate mofetil but must contact their doctor immediately. 
Bolnice bodo obveščene, da ne smejo prenehati z jemanjem mofetilmikofenolata,
Cap: light blue opaque printed ‘M' axially in black ink. 
Pokrovček: svetlo modre barve s črnim napisom “M” v smeri osi kapsule.
Transparent PVC/PVdC-aluminium blisters in pack sizes of 50 or 150 or 50 x 1 tablets per carton. 
Prozorni PVC/PVdC - aluminijasti pretisni omoti v pakiranjih po 50 ali 150 ali 50 x 1 tableta v škatli.
In some of these cases switching mycophenolate mofetil to an alternative immunosuppressant resulted in serum IgG levels returning to normal. 
V nekaj od teh primerov so se vrednosti serumskih IgG po zamenjavi mofetilmikofenolata z drugim imunosupresivom vrnile na normalo.
Use in cardiac transplant 
Uporaba pri presaditvi srca Odrasli
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Myfenax, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). 
Bolniki, ki prejemajo kombinacije imunosupresivnih zdravil, vključno z zdravilom Myfenax , so izpostavljeni povečanem tveganju nastanka limfomov in drugih malignih sprememb, zlasti kožnih (glejte poglavje 4.8).
A study of the co-administration of mycophenolate mofetil (1°g BID) and combined oral contraceptives containing ethinylestradiol (0.02°mg to 0.04°mg) and levonorgestrel (0.05°mg to 0.15°mg), desogestrel (0.15°mg) or gestodene (0.05°mg to 0.10°mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of mycophenolate mofetil on the ovulation suppressing action of the oral contraceptives. 
V študiji je 18 žensk brez presadka (drugih imunosupresivov niso jemale) sočasno prejemalo 1 g mofetilmikofenolata dvakrat na dan in kombinirane kontraceptive, ki so vsebovali etinilestradiol (0,02 mg do 0,04 mg) in levonorgestrel (0,05 mg do 0,15 mg), desogestrel (0,15 mg) ali gestoden (0,05 mg do
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal transplant recipients in the days immediately following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. 
Pri bolnikih z ledvičnim presadkom so v dneh, ki so sledili začetku zdravljenja s peroralnim ciprofloksacinom ali amoksicilinom s klavulansko kislino, poročali o zmanjšanju najnižje koncentracije mikofenolne kisline pred naslednjim odmerkom za približno 50 %.
What Myfenax looks like and contents of the pack 
Izgled zdravila Myfenax in vsebina pakiranja trde kapsule
Do not break or crush them. 
Tablet ne smete lomiti ali zmečkati.
The recommended daily dose is 8 capsules (2°g of the active ingredient) taken as 2 separate doses. 
Priporočeni dnevni odmerek je 8 kapsul (2 g zdravilne učinkovine), zaužitih kot dva posamezna odmerka.
Higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovir in comparison to the administration of aciclovir alone. 
Pri sočasni uporabi aciklovirja in mofetilmikofenolata so opazili zvečane koncentracije mikofenolglukuronida in aciklovirja v plazmi v primerjavi s samostojnim jemanjem učinkovin.
The systemic exposure at these levels is approximately equivalent to or less than 0.5°times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3°times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients (see section 4.6). 
Sistemska izpostavljenost pri tem odmerku je bila približno enaka ali manj kot 0,5-krat večja kot klinična izpostavljenost pri priporočenem kliničnem odmerku 2 g na dan pri bolnikih z ledvičnim presadkom in približno 0,3-krat večja kot klinična izpostavljenost pri priporočenem kliničnem odmerku 3 g na dan pri bolnikih s srčnim presadkom (glejte poglavje 4.6).
By interfering with enterohepatic circulation of the drug, bile acid sequestrants such as cholestyramine, reduce MPA AUC (see section 4.9). 
Adsorbenti žolčnih kislin, kot je npr. holestiramin, vplivajo na enterohepatični obtok zdravila in s tem zmanjšajo AUC mikofenolne kisline (glejte poglavje 4.9).
• chest cold, sore throat, inflammation of the sinuses, stuffy and runny nose, sneezing 
• okužba zgornjih dihal, vnetje grla, vnetje sinusov, zamašen nos in izcedek iz nosu, kihanje
Red iron oxide (E172) 
rdeči železov oksid (E172)
The systemic exposure at this dose represents 2-3°times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3-2°times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients. 
Sistemska izpostavljenost pri tem odmerku predstavlja 2- do 3-kratno klinično izpostavljenost pri priporočenem kliničnem odmerku 2 g na dan pri bolnikih z ledvičnim presadkom, in 1,3- do 2-kratno klinično izpostavljenost pri priporočenem kliničnem odmerku 3 g na dan pri bolnikih s srčnim presadkom.
• You are a child or teenager who has not started having periods. 
Turnerjev sindrom ali agenezija maternice; • ste otrok ali najstnica, ki še ni dobila prve menstruacije.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 
Benigne, maligne in neopredeljene novotvorbe
Liver Transplant 
Presaditev ledvic
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Myfenax is contraindicated in breast-feeding mothers (see section 4.3). 
Zaradi možnih resnih škodljivih vplivov mofetilmikofenolata na dojenčke, je zdravilo Myfenax pri doječih materah kontraindicirano
In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g taken twice a day [BID], morning and evening) were administered to hepatic transplant patients taking tacrolimus. 
Nasprotno, po dajanju večkratnih odmerkov mofetilmikofenolata (1,5 g dvakrat na dan, zjutraj in zvečer) bolnikom z jetrnim presadkom, ki so jemali takrolimus, se je AUC
Convulsion, hypertonia, tremor, somnolence, myasthenic syndrome, dizziness, headache, paraesthesia, dysgeusia 
Bolezni živčevja zelo pogosti pogosti konvulzije, hipertonija, tremor, somnolenca, miastenijski sindrom, omotica, glavobol, parestezija, sprememba okusa
Medicinal products that interfere with enterohepatic circulation (e.g. cholestyramine, ciclosporin A, antibiotics) 
Zdravila, ki vplivajo na glukuronidacijo (npr. izavukonazol, telmisartan)
There have been reports of aplastic anaemia and bone marrow depression in patients treated with mycophenolate mofetil, some of which have been fatal. 
Pri bolnikih, ki so se zdravili z mofetilmikofenolatom, so poročali o primerih aplastične anemije in depresije kostnega mozga, nekateri od teh so bili smrtni.
Gastrointestinal haemorrhage, peritonitis, ileus, colitis, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, stomatitis, constipation, dyspepsia, flatulence, eructation 
Bolezni prebavil zelo pogosti bruhanje, bolečina v trebuhu, diareja, navzea pogosti krvavitev v prebavilih, peritonitis, ileus, kolitis, ulkus na želodcu, ulkus na dvanajstniku, gastritis, ezofagitis, stomatitis, zaprtje, dispepsija, flatulenca, kolcanje
• The need to avoid foetal exposure: Contraceptive requirements for patients of reproductive potential prior to, during and after treatment with mycophenolate mofetil. 
• Nujnost izogibanja izpostavljenosti ploda Opisane bodo zahteve za kontracepcijo za bolnike in bolnice v rodni dobi pred, med in po zdravljenju z mofetilmikofenolatom, zahteve za kontracepcijo za spolno aktivne bolnike (vključno z vazektomiziranimi) in bolnice v rodni dobi ter potrebo po kontracepciji pred, med in po zdravljenju z mofetilmikofenolatom, vključno s podrobnostmi o času, ko je treba kontracepcijo uporabljati še po zaključku zdravljenja.
• Background information on mycophenolate mofetil teratogenicity and mutagenicity in humans. 
• Ozadje teratogenosti in mutagenosti mofetilmikofenolata pri ljudeh To poglavje bo vsebovalo pomembne informacije o teratogenosti in mutagenosti mofetilmikofenolata.
This medicinal product contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially ‘sodium-free'. 
Pomožna snov To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na trdo kapsulo, kar v bistvu pomeni ‘brez natrija'.
Gingival hyperplasia (≥1/100 to <1/10), colitis including cytomegalovirus colitis (≥1/100 to <1/10), pancreatitis (≥1/100 to <1/10) and intestinal villous atrophy. 
(≥ 1/100 do < 1/10), pankreatitis (≥ 1/100 do < 1/10) in atrofija črevesne sluznice.
Myfenax reduces your body's defence mechanism. 
Myfenax lahko poveča možnost zavrnitve vašega presadka.
• For 6°weeks after you stop taking Myfenax. 
- ves čas zdravljenja z zdravilom Myfenax; - 6 tednov po prenehanju jemanja zdravila Myfenax.
The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by coadministration of mycophenolate mofetil (see also section 5.2). 
Sočasno jemanje mofetilmikofenolata ni vplivalo na farmakokinetiko in farmakodinamiko peroralnih kontraceptivov (glejte poglavje 5.2).
In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5°g taken twice a day [BID], morning and evening) were administered to hepatic transplant patients taking tacrolimus. 
Nasprotno, po dajanju večkratnih odmerkov mofetilmikofenolata (1,5 g dvakrat na dan, zjutraj in zvečer) bolnikom z jetrnim presadkom, ki so jemali takrolimus, se je AUC takrolimusa povečala za približno 20 %.
The systemic exposure at this dose was approximately 0.5°times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3°times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients. 
Sistemska izpostavljenost pri tem odmerku je bila približno 0,5-krat večja kot klinična izpostavljenost pri priporočenem kliničnem odmerku 2 g na dan pri bolnikih z ledvičnim presadkom in približno 0,3-krat večja kot klinična izpostavljenost pri priporočenem kliničnem odmerku 3 g na dan pri bolnikih s srčnim presadkom.
Precautions to be taken before handling or administering the medicinal product Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Myfenax tablets should not be crushed. 
Ker ima mofetilmikofenolat dokazane teratogene učinke pri podganah in kuncih, filmsko obloženih tablet zdravila Myfenax ne smemo drobiti.
• You plan to become pregnant. 
• če ste noseči, načrtujete nosečnost ali menite, da bi lahko bili noseči,
Myfenax capsules at a dose of 750 mg twice daily (1.5 g daily dose). 
predpišemo kapsule zdravila Myfenax v odmerku 1 g dvakrat na dan (dnevni odmerek 2 g).
pancreatitis (≥1/100 to <1/10) and intestinal villous atrophy. 
(≥ 1/100 do < 1/10), pancreatitis (≥ 1/100 do < 1/10) in atrofija črevesne sluznice.
• Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits; 
• nenormalna ušesa (npr. nenormalna oblika ali manjkajoče zunanje uho), atrezija zunanjega sluhovoda (srednjega ušesa), • malformacije obraza, kot so razcep ustnice, razcep neba, mikrognatija in orbitalni hipertelorizem,